RAHWAY, N.J.--(BUSINESS WIRE)--Merck's WINREVAIRâ,,¢ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF. ...

In this article, I will outline my bullish thesis for the pharmaceutical giant, Merck ( MRK ). Merck is known for brands such as Keytruda, Gardasil, and Noxafil, among others. Merck has many bullish attributes. It has a bullishAs an individual investor nearing retirement I am trying to build my financial assets in order to have a fulfilling retirement. I am interested in trading both long and short; or at least using inverse ETFs, to take advantage of market declines. Having long term and short term trading ...

In this article, I will outline my bullish thesis for the pharmaceutical giant, Merck ( MRK ). Merck is known for brands such as Keytruda, Gardasil, and Noxafil, among others. Merck has many bullish attributes. It has a bullishAs an individual investor nearing retirement I am trying to build my financial assets in order to have a fulfilling retirement. I am interested in trading both long and short; or at least using inverse ETFs, to take advantage of market declines. Having long term and short term trading ...

PresentationThank you for standing by. Welcome to the Merck & Co. Inc., Rahway, New Jersey, U.S.A. Investor Event announcing the acquisition of Cidara Therapeutics. [Operator Instructions] This call is being recorded. If you have any objections, you may -- I will now turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.Peter DannenbaumVice President of Investor Relations Thank you, Denise. Good morning, everyone. Welcome to Merck's investor call highlight ...

Key Takeaways MRK offers to acquire Cidara for $9.2B, which will add phase III influenza candidate CD388 to its portfolio.The acquisition will expand MRK's respiratory offerings and support its long-term growth outlook.CD388 offers broad seasonal and pandemic flu protection with a single injection and novel mechanism.Merck (MRK) has made substantial investments in strategic mergers and acquisitions (M&A) deals over the past few years to build a more durable long-term portfolio and reinforce its growth prosp ...

Key Takeaways Merck shares have risen 9.6% in a month after recovering from a post-earnings dip.Pipeline progress and the Cidara acquisition support momentum.Gardasil weakness, product pressure and Keytruda's 2028 LOE fuel calls for a wait-and-see stance.Merck’s (MRK) shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 inhibitor, Keytruda, missed sales estimates. Merck also narro ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Merck & Co (NYSE:MRK) M&A Announcement November 17, 2025 08:00 AM ET Company ParticipantsJames Shin - Director of Biopharma Equity ResearchDaina Graybosh - Senior Managing DirectorGeoff Meacham - Managing DirectorChris Schott - Managing DirectorDean Li - President of Merck Research LaboratoriesRob Davis - CEOCaroline Litchfield - CFOAlex Hammond - Director and Head of TherapeuticsPeter Dannenbaum - Senior VP of Investor RelationsVamil Divan - Managing DirectorChirfi Guindo - CMOConference Call ParticipantsC ...

[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G 地方跟进创新药支持政策 [Table_ReportDate] 2025 年 11 月 17 日 [Table_ReportType] 医药生物行业周报（11 月第 2 周） [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（11 月 10 日-11 月 14 日）医药生物 板块收涨 3.29%，跑赢 Wind 全 A（-0.47%）和沪深 300 （-1.08%），子版块全线修复。流感数据抬头，相关概 念领涨。从细分板块来看，医药流通（5.92%）、体外 诊断（5.91%）和原料药（5.09%）领涨。从个股来看， 金迪克（61.6%）、人民同泰（61.1%）和诚达药业（58.3%） 涨幅居前，*ST 长药（-33.6%）和振德医疗（-11.3%） 和福瑞股份 ...

Core Insights - The article emphasizes the effectiveness of investing in dividend growth stocks and reinvesting dividends as a strategy for long-term wealth growth [1] Group 1: Investment Strategy - The individual investor has explored various investment styles over 25 years, concluding that dividend growth stocks are particularly beneficial for wealth accumulation [1] - The investor operates a blog focused on S&P Dividend Aristocrats and other dividend growth stocks, indicating a commitment to sharing knowledge in this area [1] Group 2: Personal Investment Position - The analyst has a beneficial long position in the shares of EMR, indicating confidence in the stock's performance [2] - The article reflects the author's personal opinions and does not involve compensation from any company mentioned, ensuring an unbiased perspective [2]